Antigen-presenting cell-mediated activation of CD8-positive, alpha-beta cytotoxic T cell

Antigen-presenting cell-mediated activation of CD8-positive, alpha-beta cytotoxic T cell describes the process where antigen-presenting cells (such as dendritic cells) present peptides via MHC class I molecules to the alpha-beta TCR on CD8+ cytotoxic T lymphocytes (CTLs). Successful activation requires a triad of signals: peptide-MHC I recognition by the TCR, costimulatory signals (e.g., CD80/CD86 binding CD28), and cytokine signaling ("signal 3"). This process is crucial for generating effective immune responses against viruses, intracellular pathogens, and cancer cells, and is tightly regulated through both innate immune triggers (e.g., pattern recognition receptors on APCs) and metabolic programming. Disruption or modulation of this process underlies many immunotherapeutic approaches, but the process itself is not, strictly speaking, a druggable target—it encompasses multiple molecular interactions and pathways.

Other names

Activation of CD8+ cytotoxic T cells by APCCD8+ T cell priming by antigen-presenting cellAPC-mediated CD8+ T cell activation

Enhancement of antigen presentation (e.g., via adjuvants targeting pattern recognition receptors on APCs); Blockade or activation of costimulatory/inhibitory signals (e.g., checkpoint inhibitors like anti-PD-1/PD-L1 or anti-CTLA-4 modulate related signaling, but not this process as a single entity)